Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib in Combination With Rituximab in Untreated Marginal Zone Lymphoma
NCT06390956Phase 2Recruiting
- Sponsor
- University of Utah
- Start
- Feb 2025
- Primary completion
- Dec 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirtobrutinib in marginal zone lymphoma (MZL), sponsored by University of Utah. Started Feb 2025; status: recruiting.
02
Drugs
pirtobrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT06390956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06390956.